No Data
No Data
All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy
Transcode Therapeutics Is Maintained at Buy by HC Wainwright & Co.
TransCode Therapeutics Analyst Ratings
An Open Letter to Shareholders of TransCode Therapeutics, Inc. Asking Stockholders to Vote FOR the Proposal to Authorize a Reverse Stock Split If Necessary
Express News | Transcode Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $10 From $20
Transcode Therapeutics | 10-K: FY2024 Annual Report